Genmab: Daratumumab is becoming an increasingly critical asset for JNJ

BUY-Top Picks, Fair Value DKK1170 (+39%)

News published on January Friday 29, 2016

Share on

For more information, please contact marketing@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth

Recent Transactions Highlights

From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year

Join our Team

Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels